UroGen Pharma Ltd.
ZUSDURI
recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for ZUSDURI in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 17h ago
“Top line results from UTOPIA were reported in November 2025, demonstrating a 77.8% three-month CR rate (95% CI, 68.3%, 85.5%).”